ABAntonios Bayas

Antonios Bayas

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Antonios Bayas has a total of 252 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Implementing the 2024 revision of the McDonald diagnostic criteria for multiple sclerosis in Germany: Practical considerations and consensus recommendations

    by Mike P. Wattjes, Antonios Bayas, Stefan Bittner, Birte Elias-Hamp, Ralf Linker, Daniela Rau, Thomas Skripuletz, Ralf Gold

    Early and reliable diagnosis of multiple sclerosis (MS) is critical for initiating an appropriate disease-modifying therapy (DMT). The 2024 revisions of the McDonald diagnostic criteria incorporate novel fluid and imaging biomarkers aiming to facilitate an accurate and timely diagnosis. The aim of this point-of-view paper is to discuss the implementation of the 2024 McDonald criteria in the clinical routine setting in context of the German Health care system and provide consensus recommendations by an interdisciplinary expert panel. A multidisciplinary panel of nine experts in the field of diagnosis and treatment of MS convened to discuss the potential advances and challenges of the clinical implementation of the 2024 McDonald criteria and develop consensus recommendations. The panel identified implementation challenges regarding limited specialized resources for the suggested additional imaging markers such as the detection of optic nerve (ON) lesions, paramagnetic rim lesions (PRLs) and the demonstration of lesions with a central vein sign (CVS) as well as the implementation of kappa free light chains (kFLC) in Germany. We advocate a stratified diagnostic approach: cerebrospinal fluid (CSF) analysis remains essential. The consideration of ON lesions, PRLs and lesions with a CVS should be reserved for diagnostic situations in which the diagnosis cannot be established with conventional MRI protocols or other methods for examination of the optic nerve. To minimize misdiagnosis and to address the complexity of treating radiologically isolated syndrome, there is a necessity of continuous professional training and nuanced, patient-centered therapeutic strategies, especially for individuals with radiologically isolated syndrome but also for atypical presentations. In conclusion, the 2024 revisions of the McDonald criteria aim to facilitate an accurate and early diagnosis of MS potentially enabling earlier MS therapy initiation. However, the routine implementation, particularly regarding the new imaging markers, requires an expansion of resources and expertise limiting the general applicability in the German healthcare system.

  • Open Access

    Impact of tobacco and alcohol consumption on disease progression and MRI in people with multiple sclerosis: results of the prospective cohort study NationMS

    by Alex Maximilian Keller, Annika Möhl, Anke Salmen, Ralf Gold, Pia Renk, Luisa Klotz, Stefan Bittner, Vinzenz Fleischer, Friedemann Paul, Klemens Ruprecht, et al.

    Background: Lifestyle factors, such as smoking cigarettes and alcohol consumption, can influence disease progression in Multiple Sclerosis (MS). Objective: This study aimed to investigate the associations of smoking cigarettes and alcohol consumption with clinical parameters in people with MS (pwMS). Design: This is a prospective cohort study, analysing data from the German NationMS cohort. Methods: We analysed data of 1374 patients recruited between 2010 and 2017. Main outcomes were Expanded Disability Status Scale (EDSS), Timed 25-Foot Walk (T25FW) and Paced Auditory Serial Addition Test (PASAT). Secondary outcomes were number of T2 and GD+ lesions. We conducted logistic and linear mixed model regression, adjusted for age, sex, educational level, MS subtype. Results: Smoking cigarettes was associated with increased odds of reaching pre-defined cut-off values for EDSS and T25FW, as well as with increased mean differences across follow-ups. Alcohol consumption was associated with decreased odds of reaching the cut-off for EDSS and T25FW. Findings for PASAT were less consistent. We found no significant associations for T2 and GD+ lesions. Conclusion: This study provides further evidence that smoking cigarettes accelerates MS progression and that pwMS should be advised to quit smoking. However, this negative impact could not be demonstrated for alcohol consumption. Reverse causation cannot be ruled out and further research in this area is warranted. Trial registration: Instead of registration in a primary trial registry, a comprehensive study protocol was published a priori and is available online: https://osf.io/3xscy .


  • Factors Associated With Disability Improvement and Worsening Independent of Attacks in Patients With AQP4-IgG+ NMOSD and MOGAD

    by Daniel Engels, Patrick Schindler, Joachim Havla, Katinka Fischer, Marius Ringelstein, Martin W. Hümmert, Franziska Bütow, Insa Schiffmann, Charlotte Schubert, Judith Bellmann-Strobl, et al.

    Disability trajectories in aquaporin-4 immunoglobulin G-seropositive neuromyelitis optica spectrum disorder (AQP4-IgG+ NMOSD) and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) are primarily driven by attack-related damage. Confirmed disability worsening (CDW) independent of attacks has been described but occurs infrequently in AQP4-IgG+ NMOSD and MOGAD. Confirmed disability improvement (CDI) has not been evaluated in large cohorts. We determined the frequency of CDI and CDW independent of attacks and identified clinical factors associated with these outcomes in AQP4-IgG+ NMOSD and MOGAD. This retrospective, multicenter cohort study analyzed data from the German Neuromyelitis Optica Study Group (NEMOS) registry. Adult patients with AQP4-IgG+ NMOSD or MOGAD and longitudinal Expanded Disability Status Scale (EDSS) assessments were included. EDSS episodes were defined as periods with ≥3 EDSS assessments without attacks, obtained ≥90 days after attack. CDW and CDI were defined as sustained EDSS increase or decrease (≥1.5 for baseline EDSS 0; ≥1.0 for EDSS 1.0-5.5; ≥0.5 for EDSS ≥6.0) confirmed after at least 6 months. The primary outcomes were annualized CDI and CDW rates. Risk factors were assessed using multivariable Anderson-Gill regression models. A total of 338 EDSS episodes of 307 patients (n: 202/105, median age at EDSS change: 56/41 years, 88/49% female, both p < 0.001; AQP4-IgG+ NMOSD/MOGAD) were included. Adjusted annualized CDI and CDW rates did not differ between AQP4-IgG+ NMOSD (CDI: 0.083, 95% CI 0.029-0.233; CDW: 0.025, 95% CI 0.007-0.092) and MOGAD (CDI: 0.057, 95% CI 0.012-0.277; CDW: 0.036, 95% CI 0.002-0.513). In AQP4-IgG+ NMOSD, a lower number of prior attacks was associated with higher CDI rates (hazard ratio [HR] 0.89, 95% CI 0.82-0.97). Younger age was associated with increased CDI rates in both AQP4-IgG+ NMOSD and MOGAD (HR 0.96, 95% CI 0.94-0.99, for both). CDI and CDW independent of attacks, although rare, occur in AQP4-IgG+ NMOSD and MOGAD. The association between fewer prior attacks and higher CDI rates in AQP4-IgG+ NMOSD underscores the importance of early attack prevention. Limitations include the retrospective design, and the limited number of CDI and CDW events.


  • Open Access

    Multimodal profiling of immune responses reveals innate-adaptive immune imbalance in human bornavirus encephalitis

    by Nicola Jungbäck, Przemyslaw Grochowski, Daniel Hieber, Moritz Dinser, Zuzanna Mielewczyk, Thomas Pfefferkorn, Birgit Muntau, Thomas Richter, Georg Rieder, Antonios Bayas, et al.

    Human bornavirus encephalitis (BVE) is a rare, emerging and fatal zoonotic disease mainly caused by the Borna disease virus 1 (BoDV-1), a non-cytolytic RNA virus. Despite increasing recognition, the immunopathogenesis of human BoDV-1 infection remains insufficiently characterised. Complete coronal and sagittal brain sections from four fatal BoDV-1 cases were analysed using digitised immunohistochemistry to quantify viral distribution and tissue responses. Transcriptome-based analyses characterised local immune cell profiles in relation to viral loads measured by RT-qPCR. BoDV-1 viral loads varied substantially between cases but showed region-specific enrichment in the basal ganglia and hippocampus, correlating with lymphocyte presence and reactive microglia and astrocytes. Immune cell deconvolution revealed viral load-dependent modulation dominated by innate immune and glial populations, including metabolic and reactive astrocyte states, IFNγ-responsive microglia, and dendritic cells, macrophages, neutrophils, basophils, and CD8⁺ T cells. This was accompanied by induction of interferon-stimulated genes, antigen presentation, protein synthesis, and oxidative stress pathways, with a transcriptional signature resembling non-lytic viral and autoimmune-like neuroinflammatory conditions rather than lytic infections. These findings support a model of BoDV-1 encephalitis characterised by a prominent innate immune response and comparatively limited adaptive immune signatures. This imbalance might potentially contribute to impaired viral clearance and extensive tissue damage, a possible relationship that warrants further investigation.

  • Open Access

    Long-term follow-up of patients with non-ischemic cerebral enhancing lesions following endovascular aneurysm treatment: magnetic resonance imaging findings, clinical course, and treatment

    by Monika Ellssel, Ansgar Berlis, Markus Naumann, Muthuraman Muthuraman, Hao Ding, Sönke Schwarting, Felix Joachimski, Christoph J. Maurer, Antonios Bayas

    Background: Non-ischemic cerebral enhancing (NICE) lesions are a rare complication following endovascular therapy (EVT) for cerebral aneurysms. Although first described in 2008, data on long-term outcome and treatment response remain limited. Objectives: In this study, we investigated the long-term follow-up of patients with NICE lesions, including magnetic resonance imaging (MRI) findings, clinical course, and treatment. Design: For this single-center ambispective observational study, we enrolled nine patients with NICE lesions after EVT for cerebral aneurysms. Methods: We analyzed patients diagnosed with NICE lesions following EVT between 2008 and 2024 at the University Hospital of Augsburg. Data collection included patients’ and procedural characteristics, clinical course, MRI findings, and response to immunotherapies. Results: We present the long-term follow-up of five patients already published and four additional cases. Nine female patients (mean age at diagnosis 50.67 ± 11.82 (± standard deviation, SD) years) were identified and analyzed with a mean follow-up of 1659.44 ± 1426.87 (SD) days, ranging from 328 to 5223 days (cumulative follow-up of 40.92 patient-years). In total, 112 MRIs were available for evaluation. Eight patients developed symptoms at a mean of 11 ± 13.41 (SD) days post-EVT, one patient remained asymptomatic. New NICE lesions during follow-up were detected in six patients, five patients developed new or increasing symptoms. All patients received glucocorticosteroids with variable duration, six patients required additional immunotherapies. At final follow-up, all patients had a favorable outcome (modified Rankin Scale 0–1), though residual symptoms persisted in four of them. Conclusion: Hitherto, this study presents the longest follow-up period of patients developing NICE lesions after EVT. NICE lesions may have a highly variable course regarding radiological and clinical characteristics, with potential for both clinical and radiological recurrence years after initial presentation. While immunosuppressive therapy appears effective, optimal treatment regimens and duration have yet to be determined. Our findings underline the importance of regular clinical and MRI controls for individual patient care in this rare condition.


  • Open Access

    Cellular and humoral vaccination response under immunotherapies—German consensus on vaccination strategies in neurological autoimmune diseases

    by Muriel Schraad, Mathias Mäurer, Anke Salmen, Tobias Ruck, Timo Uphaus, Vinzenz Fleischer, Felix Luessi, Maria Protopapa, Falk Steffen, Nicholas Hanuscheck, et al.

    Background: With the development of highly effective disease-modifying treatments, vaccinations are becoming increasingly important in people with neurological autoimmune diseases. However, questions regarding the safety and efficacy of vaccinations under immunotherapy remain. Objective: To provide recommendations on types and timing of vaccinations for people with neuroimmunological diseases under different immunotherapies. Design: Our study presents a German evidence-based expert consensus on vaccination under immunotherapies in neurological autoimmune diseases. Methods: Based on literature research, a consortium of experts evaluated the quality of evidence, integrated clinical experience, and responded to a questionnaire determining an agreement (>75%) on statements concerning vaccination upon immune therapies in neuroimmunological diseases. Results: The specific humoral and cellular response to vaccination can be compromised under alemtuzumab, azathioprine, cladribine, cyclophosphamide, CD19/CD20 antibodies (inebilizumab, ocrelizumab, ofatumumab, rituximab, ublituximab), dimethyl fumarate/diroximel fumarate, FcRn inhibitors (efgartigimod, rozanolixizumab), complement C5 inhibitors (eculizumab, ravulizumab, zilucoplan), interleukin-6 receptor antibodies (tocilizumab, satralizumab), intravenous immunoglobulins, long-term steroid administration, methotrexate, mitoxantrone, mycophenolate mofetil, tacrolimus, teriflunomide, tumor necrosis factor-α blockers, and sphingosine-1-phosphate receptor modulators (fingolimod, ozanimod, ponesimod, siponimod), as well as after autologous stem cell transplantation. The lymphocyte count can have an influence here. Overall, it is generally advisable to complete vaccination before starting immunotherapy. However, in the case of an active inflammatory disease course with possible irreversible neurological deficits, a delay in therapy initiation until immunization has been completed cannot be justified. The application of live vaccines is contraindicated for most therapies and is only recommended after a strict risk–benefit assessment. Conclusion: Vaccinations are necessary for individuals on immunotherapy to reduce the risk of infections and the associated risk of worsening neurological autoimmune diseases. However, the humoral and cellular vaccination response may be impaired under immunotherapy necessitating close monitoring. Here, we provide applicable recommendations to optimize immunization for individuals receiving immunotherapy due to a neurological autoimmune disease.


  • Open Access

    External validation of a multiple sclerosis treatment decision score using data from the ProVal-MS cohort study

    by Stefan Buchka, Alexander Hapfelmeier, Jan S. Kirschke, Verena Steuerwald, Markus Naumann, Iñaki Soto-Rey, Sven Olaf Rohr, Frank Kramer, Lars Behrens, Eva Oswald, et al.

    Background: The course of relapsing-remitting multiple sclerosis (RRMS), frequently preceded by the clinically isolated syndrome (CIS), is variable and challenging to predict. Given many treatment options available, prognostic algorithms are gaining importance in informing initial treatment decisions. However, to date, only a few externally validated exists. External validation, which involves the application of a model to independent data, is essential. Privacy-preserving federated analyses of individual-level data facilitate external validation using clinical datasets that are typically difficult to access. Objectives: Using data from the ProVal-MS study to externally validate the multiple sclerosis treatment decision score (MS-TDS), a predictive algorithm for early RRMS and CIS. The MS-TDS predicts the probability of the occurrence of at least one new or enlarging T2 lesion within 6–24 months following the onset of the disease and supports choosing between initiating platform treatment or a ‘wait-and-see’ approach. A secondary objective is to demonstrate the feasibility of privacy-preserving federated concepts within the Data Integration for Future Medicine (DIFUTURE) consortium. Design: Prospective, multicentric, non-interventional cohort study (ProVal-MS) within DIFUTURE. Methods: The calibrated MS-TDS was evaluated using the area under the receiver operating characteristic curve (AUROC) and the Brier score in both pooled and distributed settings. A decision curve analysis (DCA) was used to evaluate the net benefit of treatment decisions made by the MS-TDS in comparison to those made by treating neurologists. Results: Of the 271 individuals diagnosed with CIS or early RRMS, 202 (78.2%) received platform treatment, while 59 (21.8%) did not receive treatment. The AUROC was 0.561 (95% CI: 0.492–0.630) in the pooled analysis and 0.567 (95% CI: 0.496–0.634) in the distributed analysis. DCA demonstrated a net benefit that was commensurate with that achieved by decisions made by experienced neurologists. Conclusion: The external validation of the MS-TDS demonstrated low, non-significant predictive performance; however, it may serve as a useful complement, particularly for less-experienced neurologists. The distributed validation was found to be both feasible and compliant with data protection regulations.

  • Open Access

    Prospective study validating a multidimensional treatment decision score predicting the 24-month outcome in untreated patients with clinically isolated syndrome and early relapsing–remitting multiple sclerosis, the ProVal-MS study

    by Antonios Bayas, Ulrich Mansmann, Begum Irmak Ön, Verena S. Hoffmann, Achim Berthele, Mark Mühlau, Markus C. Kowarik, Markus Krumbholz, Makbule Senel, Verena Steuerwald, et al.

    Introduction: In Multiple Sclerosis (MS), patients´ characteristics and (bio)markers that reliably predict the individual disease prognosis at disease onset are lacking. Cohort studies allow a close follow-up of MS histories and a thorough phenotyping of patients. Therefore, a multicenter cohort study was initiated to implement a wide spectrum of data and (bio)markers in newly diagnosed patients. Methods: ProVal-MS (Prospective study to validate a multidimensional decision score that predicts treatment outcome at 24 months in untreated patients with clinically isolated syndrome or early Relapsing–Remitting-MS) is a prospective cohort study in patients with clinically isolated syndrome (CIS) or Relapsing–Remitting (RR)-MS (McDonald 2017 criteria), diagnosed within the last two years, conducted at five academic centers in Southern Germany. The collection of clinical, laboratory, imaging, and paraclinical data as well as biosamples is harmonized across centers. The primary goal is to validate (discrimination and calibration) the previously published DIFUTURE MS-Treatment Decision score (MS-TDS). The score supports clinical decision-making regarding the options of early (within 6 months after study baseline) platform medication (Interferon beta, glatiramer acetate, dimethyl/diroximel fumarate, teriflunomide), or no immediate treatment (> 6 months after baseline) of patients with early RR-MS and CIS by predicting the probability of new or enlarging lesions in cerebral magnetic resonance images (MRIs) between 6 and 24 months. Further objectives are refining the MS-TDS score and providing data to identify new markers reflecting disease course and severity. The project also provides a technical evaluation of the ProVal-MS cohort within the IT-infrastructure of the DIFUTURE consortium (Data Integration for Future Medicine) and assesses the efficacy of the data sharing techniques developed. Perspective: Clinical cohorts provide the infrastructure to discover and to validate relevant disease-specific findings. A successful validation of the MS-TDS will add a new clinical decision tool to the armamentarium of practicing MS neurologists from which newly diagnosed MS patients may take advantage. Trial registration ProVal-MS has been registered in the German Clinical Trials Register, `Deutsches Register Klinischer Studien` (DRKS)—ID: DRKS00014034, date of registration: 21 December 2018; https://drks.de/search/en/trial/DRKS00014034


  • 18fluorodeoxyglucose PET/CT as possible early diagnostic tool preceding MRI changes in Borna disease virus 1 encephalitis

    by Antonios Bayas, Martina Menacher, Constantin Lapa, Dennis Tappe, Christoph Maurer, Friederike Liesche-Starnecker, Hauke Schneider, Markus Naumann


  • Open Access

    Complement inhibition in seropositive generalized myasthenia gravis as rescue therapy in impending and effective treatment in frequently recurring impending myasthenic crisis—a case series

    by Martina Menacher, Monika Ellssel, Isabelle Kwiedor, Markus Naumann, Antonios Bayas

    In seropositive myasthenia gravis (MG), complement inhibition has been shown to be an effective and a fast-acting therapeutic option. Myasthenic crisis (MC), usually preceded by impending MC, is a life-threatening complication requiring highly effective treatments with rapid onset of action. Currently used treatment options of MC are limited, consisting mainly of symptomatic and immune therapies, that is, intravenous immunoglobulins and plasma exchange/immunoadsorption. So far, there is only very limited data on complement inhibitors in impending or manifest MC or termination of frequently recurring impending crises. Here, we report three cases of acetylcholine receptor antibody positive MG, two with impending and one case suffering from high-frequency impending MC, where complement inhibition with eculizumab or ravulizumab resulted in a rapid and sustained remission. Meningococcal vaccination, mandatory when using complement inhibitors, did not result in symptom-worsening or manifest MC.